Results 11 to 20 of about 5,561 (172)

Development and Validation of a Method for Determining Deferasirox in Human Blood Plasma by HPLC-UV

Разработка и регистрация лекарственных средств, 2022
Introduction. Deferasirox is one of the most well-known complexing drugs chelators and is successfully used in chelating therapy for the treatment of excess iron in the human body. Deferasirox is also included in the list of vital and essential medicines,
P. A. Karpova, T. N. Komarov, O. A. Archakova, D. S. Shchelgacheva, A. V. Suvorova, N. S. Bagaeva, P. K. Karnakova, I. E. Shohin   +7 more
doaj   +1 more source

Efficacy and Side Effects of Deferasirox and Deferiprone for Thalasemia Major in Children [PDF]

Pharmacology and Clinical Pharmacy Research, 2016
Thalassemia major (TM) is an inherited disease caused by defective or absent of hemoglobin chain synthesis. Regular chelation therapy is necessary to reduce excess iron in several organs of TM patients.
Asti Y. Rindarwati, Ajeng Diantini, keri Lestari   +2 more
doaj   +1 more source

Hypersensitivity myocarditis following deferasirox administration [PDF]

, 2022
We describe a case of A 73-year-old woman, receiving regular blood transfusion for 2 years as affected by myelodysplasia and under treatment with deferasirox (14 mg/kg daily; 2 tablets of 360 mg/die) in the last 2 months due to the registration of high ...
Menafra, Vito, Verardo, Romina, Labbadia, Giancarlo, Antonio Russo, Matteo, Frustaci, Andrea, Galea, Nicola   +5 more
core   +1 more source

Evaluation of Hepatic Enzymes in major β-thalassemic Patients using Deferasirox

Iraqi Journal of Pharmaceutical Sciences, 2022
β-thalassemia major is a genetic disease that causes sever defect in normal hemoglobin synthesis. The patients with β-thalassemia major need periodic blood transfusions that can result in accumulation of body iron, so treatment with iron chelating agent ...
Ahmed Yahya Dallal Bashi, Fatimah Haitham Fathi   +1 more
doaj   +1 more source

Compliance and clinical benefit of deferasirox granule and dispersible tablet formulation in pediatric patients with transfusional iron overload: in a randomized, open-label, multicenter, phase II study

Haematologica, 2023
CALYPSO (clinicaltrials gov. Identifier: NCT02435212), a randomized, open-label, multicenter, phase II study evaluated the compliance, clinical benefits, and safety of deferasirox granules and dispersible tablets (DT) in pediatric patients with iron ...
Ali T. Taher, Yasser Wali, Maria Cecilia Cruz, Pimlak Charoenkwan, Yesim Aydinok, Olena Werner, Sameera Govindaraju, Fabian Romen, Vip Viprakasit   +8 more
doaj   +1 more source

Complex interaction of deferasirox and Pythium insidiosum: iron-dependent attenuation of growth in vitro and immunotherapy-like enhancement of immune responses in vivo. [PDF]

PLoS ONE, 2015
Pythium insidiosum iron acquisition mechanisms are unknown. We previously showed that the iron chelator deferasirox had weak activity in vitro and in rabbits with experimental pythiosis. Here we show that deferasirox causes damage to P. insidiosum hyphae
Régis A Zanette, Paula E R Bitencourt, Dimitrios P Kontoyiannis, Rafael A Fighera, Mariana M Flores, Glaucia D Kommers, Priscila S Silva, Aline Ludwig, Maria B Moretto, Sydney H Alves, Janio M Santurio   +10 more
doaj   +1 more source

Comparison of oral iron chelators in the management of transfusion-dependent β-thalassemia major based on serum ferritin and liver enzymes [version 2; peer review: 2 approved]

F1000Research, 2023
Background Excess iron deriving from a chronic transfusion and dietary intake increases the risk for cardiac complications in β-thalassemia major patients.
Khairunnisa Khairunnisa, Heru Noviat Herdata, Eka Destianti Edward, Sulaiman Yusuf   +3 more
doaj   +1 more source

Genetic polymorphisms influencing deferasirox pharmacokinetics, efficacy, and adverse drug reactions: a systematic review and meta-analysis

Frontiers in Pharmacology, 2023
Objective: Deferasirox is an iron-chelating agent prescribed to patients with iron overload. Due to the interindividual variability of deferasirox responses reported in various populations, this study aims to determine the genetic polymorphisms that ...
Kittika Yampayon, Puree Anantachoti, Bunchai Chongmelaxme, Varalee Yodsurang, Varalee Yodsurang   +4 more
doaj   +1 more source

Synthesis and Characterization of Deferasirox PLGA Nanoparticles and Investigation of Toxicity in Cell Model

Journal of Mazandaran University of Medical Sciences, 2022
Background and purpose: Cancer is one of the causes of mortality worldwide. Evidence suggests that iron depletion by a chelator agent suppresses the development of some cancer cells. Deferasirox is shown to have anticancer properties.
Hamidreza Mohammadi, Javad Akhtari, Sara Assadpour, Mitra Kamali, Pedram Ebrahimnejad   +4 more
doaj  

Impact of iron chelation with deferasirox on telomere length and oxidative stress in hemodialysis patients: A randomized study

Nefrología (English Edition)
Background: Recent studies have demonstrated the effectiveness, safety, and tolerability of deferasirox in patients in peritoneal dialysis, however, its effect has not been studied in patients undergoing hemodialysis. Objective: To investigate the impact
Blanca Olivia Murillo Ortiz, Joel Ramírez Emiliano, Marcos Javier Romero Vázquez, Lauro Fabián Amador Medina, Sandra Martínez Garza, Edna Montserrat Ramos Rodríguez   +5 more
doaj   +3 more sources